The Diverse Roles of Anticonvulsants in Bipolar Disorders

References

• Ketter TA, Kimbrell TA, George MS, Sachs N, Wang PW, PostRM: Predictors of treatment response in bipolar disorder: Evidence from clinical and PET studies. J Clin Psychiatry 2002; 63(Suppl 3):21–25
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association: Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159(4 Suppl):1–50
   Web of Science ®Google Scholar
• Petty F: GABA and mood disorders: A brief review and hy-pothesis. J Affect Disord 1995; 34(4):275–281
   PubMedGoogle Scholar
• Motohashi N. Ikawa K, Kariya T: GABAB receptors are up-regulated by chronic treatment with lithium or carba-mazepine. GABA hypothesis of affective disorders? Eur J Pharmacol 1989; 166(1):95–99
   Google Scholar
• Ivlotohashi N: GABA receptor alterations after chronic lithium administration. Comparison with carbamazepine and sodium valproate. Frog Neuropsychopharmacol Biol Psychi-atry 1992; 16(4):571–579
   Google Scholar
• Bernasconi R: The GABA hypothesis of affective illness: Influence of clinically effective antimanic drugs on GABA turnover. In: Emrich HM, Aidenhoff JB, Lux HD, eds. Ba-sic Mechanisms in the Action of Lithium, Proceedings of a symposium, Bavaria, Oct 4–6,1981. Amsterdam: Elsevier Science; 1982:183–192
   Google Scholar
• Bernasconi R, Hauser K, Martin P, Shcmutz M: Biochemical aspects of the mechanism of action of valproate. In: Emrich HM, Okuma T, Milner AA, eds. Anticonvulsants in Affective Disorders. Amsterdam: Elsevier Science; 1984:1–1–32
   Google Scholar
• Post RM, Ketter TA, Joffe RT, Kramlinger KL: Lack of beneficial effects of 1-baclofen in affective disorder. Int Clin Psy-chopharmacol 1991; 6(4):197–207
   Google Scholar
• Pope HG, Jr, McElroy SL, Keck PE, Jr, Hudson JI: Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry 1991; 48(1):62–68
   PubMed Web of Science ®Google Scholar
• Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG, Garza-Trevino ES, Risch SC, Goodnick PJ, Morris DD: (The Depakote Mania Study Group): Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994; 271(12):918–924
   PubMed Web of Science ®Google Scholar
• Winsberg ME, DeGolia SG, Strong CM, Ketter TA: Dival-proex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J Affect Disord 2001; 67(1-3):207–212
   Google Scholar
• Ketter TA, Calabrese JR: Stabilization of mood from below versus above baseline in bipolar disorder: A new nomencla-ture. J Clin Psychiatry 2002; 63(2):146–151
   PubMed Web of Science ®Google Scholar
• Andersen T, Lingjaerde O: Nitrazepam (Mogadon) as a sleep-inducing agent. An analysis based on a double-blind comparison with phenobarbitone. Br J Psychiatry 1969; 115(529):1393–1397
   Google Scholar
• Ballenger JC, Burrows GD, DuPont RL, Jr, Lesser IM, Noyes R, Jr, Pecknold JC, Rifkin A, Swinson RP: Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial, I: Efficacy in short-term treatment. Arch Gen Psychiatry 1988; 45(5):413–422
   PubMed Web of Science ®Google Scholar
• Pande AC, Davidson JR, Jefferson JVV, Janney CA, Katzelnick DJ, Weisler RH, Greist JH, Sutherland SM: Treat-ment of social phobia with gabapentin: A placebo-controlled study. J Clin Psychopharmacol 1999; 19(4):341–348
   PubMed Web of Science ®Google Scholar
• Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, Taylor CB, Dager SR, Shiovitz T: Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000; 20(4):467–471
   PubMed Web of Science ®Google Scholar
• Bradwejn J, Shriqui C, Koszycki D, Meterissian G: Double-blind comparison of the effects of clonazepam and lorazepam in acute mania. J Clin Psychopharmacol 1990; 10(6):403–408
   Google Scholar
• Pande AC, Crockatt J, Janney CA, Werth JL, Tsaroucha G (Gabapentin Bipolar Disorder Study Group): Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy. Bipolar Disord 2000; 2(3, pt 2):249–255
   Google Scholar
• Rickels K, Chung HR, Csanalosi TB, Hurowitz AM, London J, Wiseman K, Kaplan M, Amsterdam JD: Alprazolam, di-azepam, imipramine, and placebo in outpatients with major depression. Arch Gen Psychiatry 1987; 44(10):862–866
   PubMed Web of Science ®Google Scholar
• Wang PW, Santosa C, Schumacher M, Winsberg ME, Strong C, Ketter TA: Gabapentin augmentation therapy in bipolar depression. Bipolar Disord 2002; 4(5):296–301
   PubMed Web of Science ®Google Scholar
• KaiyaNamba M. Yoshida H, Nakamura S: Plasma glu-tamate decarboxylase activity in neuropsychiatry. Psychiatry Res 1982; 6(3):335–343
   Google Scholar
• Nowak G, Ordway GA, Paul IA: Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res 1995; 675(1-2):157–164
   PubMedGoogle Scholar
• Auer DP, Putz B, Kraft E, Lipinski B, Schill 1, Holsboer E: Reduced glutamate in the anterior cingulate cortex in de-pression: An in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 2000; 47(4):305–313
   PubMed Web of Science ®Google Scholar
• Goff DC, Coyle JT: The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psy-chiatry 2001; 158(9):1367–1377
   PubMed Web of Science ®Google Scholar
• Cai Z. McCaslin PP: Amitriptyline, desipramine, cyprohepta-dine and carbamazepine, in concentrations used therapeuti-cally, reduce kainate- and N-methyl-D-aspartate-induced in-tracellular Ca2+ levels in neuronal culture. Eur J Pharmacol 1992; 219(1):53–57
   Google Scholar
• Nowak G, Trullas R. Layer RT, Skolnick P. Paul IA: Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J Pharmacol Exp Ther 1993; 265(3):1380–1386
   PubMedGoogle Scholar
• Gottesfeld Z: Effect of lithium and other alkali metals on brain chemistry and behavior, I: Glutamic acid and GABA in brain regions. Psychopharmacologia 1976; 45(3):239–242
   Google Scholar
• Marcus SR, Nadiger HA, Chandrakala MV, Rao TI, Sadasivudu B: Acute and short-term effects of lithium on glutamate metabolism in rat brain. Biochem Pharmacol 1986; 35(3):365–369
   Google Scholar
• Hokin LE, Dixon JF, Los GV: A novel action of lithium: Stim-ulation of glutamate release and inositol 1,4,5 trisphosphate accumulation via activation of the N-methyl D-aspartate re-ceptor in monkey and mouse cerebral cortex slices. Adv En-zyme Regul 1996; 36:229–244
   Google Scholar
• Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD : (Lamictal 602 Study Group): A double-blind placebo-controlled study of lamotrigine monotherapy in out-patients with bipolar I depression. J Clin Psychiatry 1999; 60(2):79–88
   PubMed Web of Science ®Google Scholar
• Twyman RE, Rogers CJ, Macdonald RL: Differential regu-lation of gamma-aminobutyric acid receptor channels by di-azepam and phenobarbital. Ann Neurol 1989; 25(3):213–220
   PubMed Web of Science ®Google Scholar
• MacKinnon DF, Zandi PP, Cooper J, Potash JB, Simpson SG, Gershon E, Nurnberger J, Reich T, DePaulo JR: Co-morbid bipolar disorder and panic disorder in families with a high prevalence of bipolar disorder. Am J Psychiatry 2002; 159(430–35
   Google Scholar
• Lampe H, Bigalke H: Carbamazepine blocks NMDA-activated currents in cultured spinal cord neurons. Neurore-port 1990; 1(426–28
   Google Scholar
• Post RM: Time course of clinical effects of carbamazepine: Implications for mechanisms of action. J Clin Psychiatry 1988; 49(4 Suppl):35–48
   Google Scholar
• Ambrosio AF, Soares-Da-Silva P, Carvalho CM, Carvalho AP: Mechanisms of action of carbamazepine and its deriva-tives, oxcarbazepine, B IA 2-093, and B IA 2-024. Neurochem Res 2002; 27(1-2):121–130
   PubMed Web of Science ®Google Scholar
• Ketter TA, Post RM, Pazzaglia PJ, Marangell LB, George MS, Callahan AM: Carbamazepine. In: Goodnick P, ed. Mania: Clinical and Research Perspectives. Washington: American Psychiatric Press: 1998:263–300
   Google Scholar
• Post RM, Uhde TW, Roy-Byrne PP, Joffe RT: Antidepressant effects of carbamazepine. Am J Psychiatry 1986; 143(1):29–34
   Google Scholar
• Uhde TW, Stein MB, Post RM: Lack of efficacy of carba-mazepine in the treatment of panic disorder. Am J Psychiatry 1988; 145(9):1104–1109
   Google Scholar
• Mattson RH, Cramer JA, Collins JF: (The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group): A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992: 327(11):765–771
   Google Scholar
• Rattya J, Vainionpaa L, Knip M, Lanning P, Isojarvi JI: The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999; 103(3):588–593
   PubMed Web of Science ®Google Scholar
• Ketter TA, Post RM, Worthington K: Principles of clinically important drug interactions with carbamazepine, Part. J Clin Psychopharmacol 1991; 11(3):198–203
   Google Scholar
• Ketter TA, Post RM, Worthington K: Principles of clinically important drug interactions with carbamazepine, Part II. J Clin Psychopharmacol 1991; 11(5):306–313
   Google Scholar
• Tohen M, Castillo J, Baldessarini RJ, Zarate C, Jr, Kando JC: Blood dyscrasias with carbamazepine and valproate: A pharmacoepidemiological study of 2,228 patients at risk. Am J Psychiatry 1995; 152(3):413–418
   Google Scholar
• Greil W. Kleindienst N. Erazo N, Muller-Oerlinghausen B: Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 1998; 18(6):455–460
   Google Scholar
• Löscher W: Valproate: A reappraisal of its pharmacodynamicproperties and mechanisms of action. Frog Neurobiol 1999; 58(431–59
   Google Scholar
• Keck PE, Jr, Taylor VE, Tugrul KC, McElroy SL, Bennett JA: Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 1993; 33(7):542–546
   Google Scholar
• Hirschfeld RM, Allen MH, McEvoy JP, Keck PE, Jr, Russell JM: Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. J Clin Psychiatry 1999; 60(12):815–818
   Google Scholar
• Bowden CL, Janicak PG, Orsulak IP, Swann AC, Davis JM, Calabrese JR, Goodnick P, Small JO, Rush AJ, Kimmel SE, Risch SC, Morris DD: Relation of serum valproate concentra-tion to response in mania. Am J Psychiatry 1996; 153(6):765–770
   PubMed Web of Science ®Google Scholar
• Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG, Jr, ChouJC, Keck PE, Jr, Rhodes LJ, Swann AC, Hirschfeld RM, Wozniak PJ (Divalproex Maintenance Study Group): A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000; 57(5):481–489
   PubMed Web of Science ®Google Scholar
• Ketter TA, Malow BA, Flamini R, Ko D, White SR, Post RM, Theodore WH: Felbamate monotherapy has stimulant-like effects in patients with epilepsy. Epilepsy Res 1996; 23(2):129–137
   PubMed Web of Science ®Google Scholar
• Petroff OA, Rothman DL, Behar KL, Lamoureux D, Mattson RH: The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 1996; 39(1):95–99
   PubMed Web of Science ®Google Scholar
• Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, Dooley DJ, Boden P, Singh L: A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998; 29(3):233–249
   PubMed Web of Science ®Google Scholar
• Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff ON: The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996; 271(10):5768–5776
   PubMed Web of Science ®Google Scholar
• Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, Luckenbaugh DA, Cord-Locatelli G, Leverich GS, Post RM: A placebo controlled evaluation of lamotrig-ine and gabapentin monotherapy in mood disorders. J Clin Psychopharmacology 2000; 20(4):607–614
   Google Scholar
• Frye MA, Kimbrell TA, Dunn RT, Piscitelli S, Grothe D, Vanderham E, Cord-Locatelli G, Post RM, Ketter TA: Gabapentin does not alter single-dose lithium pharmacoki-netics. J Clin Psychopharmacol 1998; 18(6):461–464
   Google Scholar
• Backonja MM: Gabapentin monotherapy for the symp-tomatic treatment of painful neuropathy: A multicenter, double-blind, placebo-controlled trial in patients with dia-betes mellitus. Epilepsia 1999; 40(Suppl 6):S57–S59
   Google Scholar
• Rowbotham M, Harden N. Stacey B, Bernstein P, Magnus-Miller L: Gabapentin for the treatment of postherpetic neuralgia; A randomized controlled trial. JAMA 1998: 280(21):1837–1842
   PubMed Web of Science ®Google Scholar
• Xie X, Hagan RM: Cellular and molecular actions of lam-otrigine: Possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology 1998; 38(3):119–130
   PubMed Web of Science ®Google Scholar
• Ketter TA, Manji HK, Post RM: Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol (in press)
   Google Scholar
• Marson AG, Kadir ZA, Hutton JL, Chadwick DW: The new antiepileptic drugs: A systematic review of their efficacy and tolerability. Epilepsia 1997; 38(8):859–880
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Sullivan JR, Bowden CL, Suppes T, Goldberg JF, Sachs GS, Shelton MD, Goodwin FK. Frye MA, Kusumakar V: Rash in multicenter trials of lamotrigine in mood disorders: Clinical relevance and management. J Clin Psychiatry 2002: 63(11):1012–1019
   PubMed Web of Science ®Google Scholar
• Warner T, Patsalos PN, Prevett M. Elyas AA, Duncan JS: Lamotrigine-induced carbamazepine toxicity: An interac-tion with carbamazepine-10,11-epoxide. Epilepsy Res 1992: 11(2):147–150
   Google Scholar
• Malminiemi K, Keranen T, Kerttula T, Moilanen E, Ylitalo P: Effects of short-term lamotrigine treatment on pharmacokinetics of carbamazepine. Int J Clin Pharmacol Ther 2000; 38(11):540–545
   Google Scholar
• Anderson GD, Yau MK, Gidal BE, Harris SJ, Levy RH, Lai AA, Wolf KB, Wargin WA, Dren AT: Bidirectional interac-tion of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther 1996; 60(2):145–156
   PubMed Web of Science ®Google Scholar
• Kaufman KR, Gerner R: Lamotrigine toxicity secondary to sertraline. Seizure 1998; 7(2):163–165
   PubMedGoogle Scholar
• Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, Kusumakar V. Ascher JA, Earl NL, Greene PL, Monaghan ET (Lamictal 614 Study Group): A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000; 61(11):841–850
   Google Scholar
• Shank RP, Gardocki SF, Streeter AJ, Maryanoff BE: An overview of the preclinical aspects of topiramate: Pharma-cology, pharmacokinetics, and mechanism of action. Epilep-sia 2000; 41(Suppl 1):S3–S9
   Google Scholar
• White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH: Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neu-rons and increases seizure threshold. Epilepsy Res 1997; 28(3):167–179
   PubMed Web of Science ®Google Scholar
• Petroff OA, Hyder F, Mattson RH, Rothman DL: Topiramate increases brain GABA, homocamosine, and pyrrolidinone in patients with epilepsy. Neurology 1999; 52(3):473–478
   PubMedGoogle Scholar
• Kanda T, Kurokawa M, _Tamura S. Nakamura J, Ishii A, Kuwana Y, Serikawa T, Yamada J, Ishihara K, Sasa M: Top-iramate reduces abnormally high extracellular levels of glu-tamate and aspartate in the hippocampus of spontaneously epileptic rats (SER). Life Sci 1996; 59(19):1607–1616
   Google Scholar
• Rosenfeld WE: Topiramate: A review of preclinical, pharma-cokinetic, and clinical data. Clin Ther 1997; 19(6):1294–1308
   PubMed Web of Science ®Google Scholar
• Rhee DJ, Goldberg MJ, Parrish RK: Bilateral angle-closure glaucoma and ciliary body swelling from topiramate. Arch Ophthalmol 2001; 119(11):1721–1723
   Google Scholar
• Rosenfeld WE, Doose DR, Walker SA, Nayak RK: Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 1997; 38(3):317–323
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E. Henriksen O, Dam M, Mikkelsen M, Schmidt D, Reid S, Reife R, Kramer L. Pledger G, Karim R: Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996; 37(6):539–543
   Google Scholar
• McElroy SL, Arnold LM, Shapira NA, Keck PE, Jr, Rosenthal NR, Karim MR, Kamin M, Hudson JI:Topiramate in the treatment of binge eating disorder associated with obe-sity: A randomized, placebo-controlled trial. Am J Psychiatry 2003; 160(2):255–261
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Keck PE, Jr, McElroy SL, Shelton MD: A pilot study of topiramate as monotherapy in the treatment of acute mania. J Clin Psychopharmacol 2001; 21(3):340–342
   PubMed Web of Science ®Google Scholar
• McIntyre RS. Mancini DA, McCann S. Srinivasan S. Sagman D, Kennedy SF: Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: A preliminary single-blind study. Bipolar Disord 2002; 4(3):207–213
   Google Scholar
• Me drum BS, Chapman AG: Basic mechanisms of gabi-tril (tiagabine) and future potential developments. Epilepsia 1999; 40\(Suppl 9):S2–S6
   Google Scholar
• Kaufman KR: Adjunctive tiagabine treatment of psychiatric disorders: Three cases. Ann Clin Psychiatry 1998; 10(4):181–184
   Google Scholar
• Schaffer L, Schaffer C, Howe J: An open case series on the utility of tiagabine as an augmentation in refractory bipolar outpatients. J Affect Disord 2002; 71(1-3):259
   Google Scholar
• Physicians' desk reference, 57th ed. Montvale, NJ: Thomson PDR; 2003
   Google Scholar
• Grunze H, Erfurth A, Marcuse A, Amann B, Normann C, Walden J: Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry 1999; 60(11):759–762
   PubMed Web of Science ®Google Scholar
• Schapel G, Chadwick D: Tiagabine and non-convulsive status epilepticus. Seizure 1996; 5(2):153–156
   PubMedGoogle Scholar
• Emrich HM: Studies with (Trileptal) oxcarbazepine in acute mania. Int Clin Psychopharmacology 1990; 5(Suppl 1):83–88
   Google Scholar
• Friis ML, Kristensen O, Boas J, Dalby M, Deth SH, Gram L, Mikkelsen M, Pedersen B, Sabers A, Worm-Petersen J, Andersen D, Jensen PK: Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Ne u-rol Scand 1993; 87(3):224–227
   PubMed Web of Science ®Google Scholar
• Smith PE: Clinical recommendations for oxcarbazepine. Seizure 2001; 10(2):87–91
   Google Scholar
• Baruzzi A, Albani F, Riva R: Oxcarbazepine: Pharmacoki-netic interactions and their clinical relevance. Epilepsia 1994; 35(3):S14—S19
   Google Scholar
• Keranen T, Jolkkonen J, Jensen PK, Menge GP, Andersson P: Absence of interaction between oxcarbazepine and ery-thromycin. Acta Neurol Scand 1992; 86(2):120–123
   PubMed Web of Science ®Google Scholar
• Fattore C, Cipolla G, Gatti G, Limido GL, Sturm Y, Bernasconi C, Perucca E: Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 1999; 40(6):783–787
   PubMed Web of Science ®Google Scholar
• Oommen IU, Mathews S: Zonisamide: A new antiepileptic drug. Clin Neuropharmacol 1999; 22(4):192–200
   Google Scholar
• Mimaki T, Suzuki Y, Tagawa T, Karasawa T, Yabuuchi H: Interaction of zonisamide with benzodiazepine and GABA receptors in rat brain. Med J Osaka Univ 1990; 39(1–4):13--17
   Google Scholar
• Okada M, Kawata Y, Mizuno K, Wada K, Kondo T, Kaneko S: Interaction between Ca2+, K+, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. Br J Pharmacol 1998; 124(6):1277–1285
   PubMed Web of Science ®Google Scholar
• Chadwick DW, Marson AG: Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2002(2):CD001416
   Google Scholar
• Kanba S. Yagi G, Kamijima K, Suzuki T, Tajima O, Otaki J, Arata E, Koshikawa H, Nibuya M, Kinoshita N, Asai M: The first open study of zonisamide, a novel anticonvillsant, shows efficacy in mania. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18(4):707–715
   Google Scholar
• Nash EM, Sangha KS: Levetiracetam. Am J Health Syst Pharm 2001; 58(13):1195–1199
   Google Scholar
• Zona C, Niespodziany I, Marchetti C, Klitgaard H, Bernardi G, Margineanu DG: Levetiracetam does not modulate neu-ronal voltage-gated Na+ and T-type Ca2+ currents. Seizure 2001; 10(4):279–286
   PubMed Web of Science ®Google Scholar
• Fraser CM, Sills GJ, Forrest G, Thompson GO, Brodie MJ: Effects of anti-epileptic drugs on glutamine synthetase ac-tivity in mouse brain. Br J Pharmacol 1999; 126(7):1634–1638
   Google Scholar
• Sills GJ, Leach JP, Fraser CM, Forrest G, Patsalos PN, Brodie MJ: Neurochemical studies with the novel anticonvulsant lev-etiracetam in mouse brain. Fur J Pharmacol 1997; 325(1):35–40
   Google Scholar
• Loscher W, Honack D, Bloms-Funke P: The novel antiepilep-tic drug levetiracetam (ucb L059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticu-lata. Brain Res 1996; 735(2):208–216
   Google Scholar
• Rigo JM, Hans G, Nguyen L, Rocher V, Belachew S, Malgrange B, Leprince P, Moonen G, Selak I, Matagne A, Klitgaard H: The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 2002; 136(5):659–672
   PubMed Web of Science ®Google Scholar
• Poulain P. Margineanu DG: Levetiracetam opposes the ac-tion of GABAA antagonists in hypothalamic neurones. Neu-ropharrnacology 2002; 42(3):346–352
   Google Scholar
• French J. Edrich P. Cramer JA: A systematic review of the safety profile of levetiracetam: A new antiepileptic drug. Epilepsy Res 2001; 47(1-2):77–90
   Google Scholar
• Goldberg JF, Burdick KE: Levetiracetam for acute mania. Am J Psychiatry 2002; 159(1):148
   Google Scholar